TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 14687744

Group type: EXPERIMENTAL
Intervention: Conjugated equine estrogens 0.625 mg combined with medroxyprogesterone acetate 5 mg (CEE/MPA, n=31)
Number of subjects: 95

Group type: EXPERIMENTAL
Intervention: Tibolone 2.5 mg (n=42)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Control group (n=22)
Number of subjects: 95
Study: 11302565

Group type: EXPERIMENTAL
Intervention: Trimipramine
Number of subjects: 19

Group type: COMPARATOR
Intervention: Fluoxetine
Number of subjects: 19
Study: 9215327

Group type: EXPERIMENTAL
Intervention: Educational/consultation intervention
Number of subjects: 446

Group type: COMPARATOR
Intervention: Control home
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: All three homes
Number of subjects: 446

Group type: EXPERIMENTAL
Intervention: Total sample
Number of subjects: 446
Study: 8483562

Group type: EXPERIMENTAL
Intervention: MMM (mitomycin 7‐8 mg/m2 i.v. every 6 weeks; mitoxantrone 7‐8 mg/m2 i.v. every 3 weeks; methotrexate 35 mg/m2 i.v. every 3 weeks)
Number of subjects: 347

Group type: COMPARATOR
Intervention: VAC (vincristine 1.4 mg/m2 every 3 weeks, anthracycline 30 mg/m2 every 3 weeks, cyclophosphamide 400 mg/m2 every 3 weeks)
Number of subjects: 347

Group type: COMPARATOR
Intervention: CMF (cyclophosphamide 100 mg orally, days 1‐14; methotrexate 35 mg/m2 i.v. days 1 and 8; 5‐fluorouracil 1 g i.v. days 1 and 8)
Number of subjects: 347
Study: 2880718

Group type: EXPERIMENTAL
Intervention: Disopyramide
Number of subjects: 68

Group type: COMPARATOR
Intervention: Lignocaine
Number of subjects: 68
Study: 29705473

Group type: EXPERIMENTAL
Intervention: Alexander Technique lessons
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Acupuncture sessions
Number of subjects: 30

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 30
Study: 30067323

Group type: EXPERIMENTAL
Intervention: Injection of botulinum toxin A
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Subjective evaluation by doctor and patients
Number of subjects: 20
Study: 24850111

Group type: EXPERIMENTAL
Intervention: IPM‐QRB criteria
Number of subjects: 4

Group type: COMPARATOR
Intervention: Cochrane review criteria
Number of subjects: 4
Study: 22901959

Group type: EXPERIMENTAL
Intervention: Lobectomy
Number of subjects: 184

Group type: EXPERIMENTAL
Intervention: Segmental resection with regional lymph node dissection
Number of subjects: 184

Group type: COMPARATOR
Intervention: Segmental resection with selected lymph node resection
Number of subjects: 184

Group type: COMPARATOR
Intervention: Group 1 (poor pulmonary function)
Number of subjects: 184
Study: 21040375

Group type: EXPERIMENTAL
Intervention: Racemic ketamine (3 mg kg(‐1))
Number of subjects: 31

Group type: EXPERIMENTAL
Intervention: S-ketamine (1.5 mg kg(‐1))
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (xylazine premedication)
Number of subjects: 31

Group type: COMPARATOR
Intervention: Control group (isoflurane maintenance)
Number of subjects: 31
Study: 18657670

Group type: EXPERIMENTAL
Intervention: Implantable cardioverter defibrillator (ICD)
Number of subjects: 458

Group type: COMPARATOR
Intervention: Standard medical therapy
Number of subjects: 458
Study: 16317124

Group type: EXPERIMENTAL
Intervention: Linoleic acid diet
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: Stearic acid diet
Number of subjects: 45

Group type: COMPARATOR
Intervention: Oleic acid diet
Number of subjects: 45
Study: 11979003

Group type: EXPERIMENTAL
Intervention: Octreotide or somatostatin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Specialist centres
Number of subjects: 0

Group type: COMPARATOR
Intervention: Nonspecialist centres
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Common complications
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hospital stay
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Re-operation rate
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Major complications
Number of subjects: 0
Study: 9794903

Group type: EXPERIMENTAL
Intervention: Octreotide 100 microgram subcutaneously three times a day for 15 days
Number of subjects: 262

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 262
Study: 7620115

Group type: EXPERIMENTAL
Intervention: Omeprazole 20 mg daily
Number of subjects: 128

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 128
Study: 2693850

Group type: COMPARATOR
Intervention: Dacarbazine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Dacarbazine-vindesine
Number of subjects: 119
Study: 323025

Group type: EXPERIMENTAL
Intervention: 0.5 mg physostigmine i.v.
Number of subjects: 14

Group type: COMPARATOR
Intervention: Saline placebo i.v.
Number of subjects: 14
Study: 30762190

Group type: EXPERIMENTAL
Intervention: myDEx intervention
Number of subjects: 180
Study: 28823787

Group type: EXPERIMENTAL
Intervention: Parental identification of normal sexualized behaviors
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Parental identification of concerning or harmful sexualized behaviors
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Parental intervention responses
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Parental identification of behaviors in very young children (0-4 years)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Comparison of intervention responses based on relationship to victim/perpetrator
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Comparison of intervention responses when both victim and perpetrator are siblings
Number of subjects: 244
Study: 24245753

Group type: EXPERIMENTAL
Intervention: scaling‐polishing + tooth brushing + tongue brushing
Number of subjects: 151

Group type: COMPARATOR
Intervention: scaling‐polishing + tooth brushing
Number of subjects: 151
Study: 23586374

Group type: EXPERIMENTAL
Intervention: Epithelium-off collagen cross-linking (CXL)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Confocal microscopy
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Scheimpflug imaging
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Optical coherence tomography
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Slit-lamp biomicroscopy
Number of subjects: 14
Study: 21281542

Group type: EXPERIMENTAL
Intervention: Computer-tailored nutrition advice (Food-O-Meter)
Number of subjects: 621

Group type: COMPARATOR
Intervention: Standardised advice (Control)
Number of subjects: 621
Study: 19299903

Group type: EXPERIMENTAL
Intervention: UFT with leucovorin (LV)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT in combination with oxaliplatin (TEGAFOX)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: UFT in combination with irinotecan (TEGAFIRI)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEGAFOX and TEGAFIRI (alternating cycles)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: TEGAFIRI and cetuximab
Number of subjects: 0
Study: 17000944

Group type: EXPERIMENTAL
Intervention: History of diabetes mellitus (DM)
Number of subjects: 97771
Study: 14962401

Group type: EXPERIMENTAL
Intervention: Invalid preparation for the irrelevant task
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Invalid preparation
Number of subjects: 0
Study: 11739444

Group type: EXPERIMENTAL
Intervention: Acipimox (500 mg)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9
Study: 9192957

Group type: EXPERIMENTAL
Intervention: Preoperative radiotherapy (25-25.5 Gy over 5-7 days)
Number of subjects: 1316
Study: 1532222

Group type: EXPERIMENTAL
Intervention: Group A (n = 18) trained from 72 degrees to 36 degrees of lumbar flexion
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Group B (n = 14) trained from 36 degrees to 0 degree of lumbar flexion
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Group AB (n = 16) trained from 72 degrees to 0 degree of lumbar flexion
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (C; n = 10) that did not train
Number of subjects: 58
Study: 3887870

Group type: EXPERIMENTAL
Intervention: PPC (amino acid preparation)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control (mixture of two pollen extracts)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: PPC
Number of subjects: 62

Group type: COMPARATOR
Intervention: Control
Number of subjects: 62
Study: 31742631

Group type: EXPERIMENTAL
Intervention: Ubrogepant 50 mg
Number of subjects: 1686

Group type: EXPERIMENTAL
Intervention: Ubrogepant 25 mg
Number of subjects: 1686

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1686
Study: 29071969

Group type: EXPERIMENTAL
Intervention: Acupuncture + nutrition consultation
Number of subjects: 71

Group type: COMPARATOR
Intervention: Simple nutrition consultation
Number of subjects: 71
Study: 25592006

Group type: EXPERIMENTAL
Intervention: Caffeine (5 mg/kg body weight)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Green coffee bean extract (10 mg/kg, 5 mg/kg chlorogenic acid)
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study: 23503735

Group type: EXPERIMENTAL
Intervention: High-frequency chest wall oscillation therapy
Number of subjects: 50

Group type: COMPARATOR
Intervention: Standard treatment (bronchodilators, antibiotics, oxygen, patient education)
Number of subjects: 50
Study: 21472632

Group type: EXPERIMENTAL
Intervention: 10-week aerobic running exercise program (3 workouts per week)
Number of subjects: 16
Study: 18263663

Group type: EXPERIMENTAL
Intervention: Varenicline (1 mg twice daily for 12 weeks)
Number of subjects: 746

Group type: COMPARATOR
Intervention: Transdermal NRT (21 mg/day reducing to 7 mg/day for 10 weeks)
Number of subjects: 746

Group type: EXPERIMENTAL
Intervention: Varenicline
Number of subjects: 746

Group type: COMPARATOR
Intervention: Transdermal NRT
Number of subjects: 746
Study: 16426449

Group type: EXPERIMENTAL
Intervention: Active Physical Treatment (APT)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Cognitive-Behavioral Treatment (CBT)
Number of subjects: 223

Group type: EXPERIMENTAL
Intervention: Combined Treatment (CT) of APT and CBT
Number of subjects: 223

Group type: COMPARATOR
Intervention: Waiting List (WL)
Number of subjects: 223
Study: 12483414

Group type: EXPERIMENTAL
Intervention: Fluor‐18 2‐fluorodeoxyglucose (FDG) imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: N‐[(11)C‐methyl]‐L‐deuterodeprenyl (DED) imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: Oxygen‐15 labelled water scan
Number of subjects: 15

Group type: COMPARATOR
Intervention: Computed tomography and magnetic resonance imaging
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PET examinations
Number of subjects: 15
Study: 10957749

Group type: EXPERIMENTAL
Intervention: Moderate consumption of red wine with evening dinner for 3 weeks
Number of subjects: 0

Group type: COMPARATOR
Intervention: Red grape juice consumption
Number of subjects: 0
Study: 8645774

Group type: EXPERIMENTAL
Intervention: Divalproex sodium
Number of subjects: 63

Group type: COMPARATOR
Intervention: Lithium
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 1468186

Group type: EXPERIMENTAL
Intervention: ponalrestat 600 mg/day
Number of subjects: 32

Group type: COMPARATOR
Intervention: matching placebo
Number of subjects: 32
Study: 6731770

Group type: EXPERIMENTAL
Intervention: Premedicated with TDP (trimeprazine, droperidol, physeptone, and atropine)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Premedicated with trimeprazine and atropine
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Premedicated with papaveretum and hyoscine
Number of subjects: 90

Group type: COMPARATOR
Intervention: Unpremedicated children
Number of subjects: 90
Study: 3700848

Group type: EXPERIMENTAL
Intervention: Hypnotic analgesia
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stress inoculation training
Number of subjects: 60

Group type: COMPARATOR
Intervention: Stress inoculation training defined as hypnosis
Number of subjects: 60
Study: 29463231

Group type: EXPERIMENTAL
Intervention: Immunosuppressive therapy adherence assessment
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Multilevel correlates assessment
Number of subjects: 0
Study: 28606219

Group type: EXPERIMENTAL
Intervention: Dietary calcium intake (mean 870 mg/d)
Number of subjects: 323
Study: 26206258

Group type: EXPERIMENTAL
Intervention: Chemotherapy with anthracyclines (epirubicin -> cyclophosphamide, methotrexate and fluorouracil (CMF))
Number of subjects: 921

Group type: COMPARATOR
Intervention: Chemotherapy without anthracyclines (CMF)
Number of subjects: 921
Study: 24002795

Group type: EXPERIMENTAL
Intervention: Rosuvastatin 20 mg/d
Number of subjects: 10886

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10886
Study: 21441356

Group type: EXPERIMENTAL
Intervention: High concurrent self-regulatory efficacy (SRE) group
Number of subjects: 49

Group type: COMPARATOR
Intervention: Low concurrent self-regulatory efficacy (SRE) group
Number of subjects: 49
Study: 17335643

Group type: EXPERIMENTAL
Intervention: Active rTMS treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: rTMS treatment with reduced frequency (from two sessions per day to one)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Treatment for TEM (decrease or discontinuation of antidepressant and/or rTMS treatment and/or use of anti-manic medication)
Number of subjects: 13
Study: 16996855

Group type: EXPERIMENTAL
Intervention: 32 mg candesartan cilexetil
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 120
Study: 12790064

Group type: EXPERIMENTAL
Intervention: Innovative postoperative pain management techniques
Number of subjects: 0

Group type: COMPARATOR
Intervention: Standard-of-care treatments for postoperative pain management
Number of subjects: 0
Study: 10971422

Group type: EXPERIMENTAL
Intervention: Preservation of ilioinguinal nerve
Number of subjects: 20

Group type: COMPARATOR
Intervention: Division of ilioinguinal nerve
Number of subjects: 20
Study: 8732473

Group type: COMPARATOR
Intervention: Menorest (transdermal oestradiol) at doses of 50, 75, 100 micrograms/day in study 201 and 25, 50, 75 micrograms/day in study 305, administered cyclic sequential or continuous sequential with dydrogesterone 20 mg/day during the last 14 days.
Number of subjects: 480

Group type: COMPARATOR
Intervention: Menorest (transdermal oestradiol)
Number of subjects: 480
Study: 1426355

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 200 mg/d
Number of subjects: 75

Group type: EXPERIMENTAL
Intervention: Ascorbic acid 1000 mg/d
Number of subjects: 75

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study: 6697071

Group type: EXPERIMENTAL
Intervention: 20 ml normal saline
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 80 mg Depomedrone in normal saline made up to 20 ml
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: 20 ml 0.25% bupivacaine solution
Number of subjects: 0

Group type: COMPARATOR
Intervention: Needling with a standard Touhy injection needle into the interspinous ligament (no injection)
Number of subjects: 0
Study: 29294892

Group type: EXPERIMENTAL
Intervention: Exposure to bullying and mistreatment by siblings
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Exposure to verbal abuse and quarrel within family members
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Male children
Number of subjects: 800

Group type: EXPERIMENTAL
Intervention: Children from families that always fight and parents with exposure to childhood maltreatment
Number of subjects: 800
Study: 30278853

Group type: EXPERIMENTAL
Intervention: PS training
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: WM training
Number of subjects: 83

Group type: COMPARATOR
Intervention: No-training control group
Number of subjects: 83
Study: 28166785

Group type: EXPERIMENTAL
Intervention: Initial DMARD-monotherapy (sulfasalazine (SSZ) or methotrexate (MTX))
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Initial MTX / prednisolone-bridging
Number of subjects: 94

Group type: EXPERIMENTAL
Intervention: Initial combination MTX/etanercept
Number of subjects: 94

Group type: COMPARATOR
Intervention: Control group (Initial DMARD-monotherapy and Initial MTX / prednisolone-bridging)
Number of subjects: 94
Study: 25476268

Group type: EXPERIMENTAL
Intervention: SMS reminders after making an appointment
Number of subjects: 1786

Group type: COMPARATOR
Intervention: Control group received a leaflet on preparation instructions
Number of subjects: 1786

Group type: EXPERIMENTAL
Intervention: SMS reminders
Number of subjects: 1786
Study: 23628001

Group type: EXPERIMENTAL
Intervention: Baclofen (10 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 21355003

Group type: EXPERIMENTAL
Intervention: Trastuzumab (8 mg/kg loading dose, 6 mg/kg every 3 weeks for 1 year) plus chemotherapy
Number of subjects: 300

Group type: COMPARATOR
Intervention: Trastuzumab monotherapy
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: Trastuzumab (with chemotherapy)
Number of subjects: 300
Study: 19473468

Group type: EXPERIMENTAL
Intervention: Clitoral blood volume (CBV) measurement during erotic film clips
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vaginal pulse amplitude (VPA) measurement during erotic film clips
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Skin conductance levels (SCL) measurement during erotic film clips
Number of subjects: 30

Group type: COMPARATOR
Intervention: Comparison of CBV and VPA at the end of the erotic film clip presentation
Number of subjects: 30
Study: 17299516

Group type: EXPERIMENTAL
Intervention: Psilocybin 115 microg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Psilocybin 215 microg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Psilocybin 315 microg/kg
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Psilocybin
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 15598915

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin (HCV genotype 1 or 4)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin (HCV genotype 1 or 4)
Number of subjects: 412

Group type: EXPERIMENTAL
Intervention: Peginterferon alfa-2b plus ribavirin (HCV genotype 2, 3, or 5)
Number of subjects: 412

Group type: COMPARATOR
Intervention: Standard interferon alfa-2b plus ribavirin (HCV genotype 2, 3, or 5)
Number of subjects: 412
Study: 11758296

Group type: EXPERIMENTAL
Intervention: Various treatment options for functional dyspepsia
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Specific checklists with clinical and economical items
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Methodologic rigor in economic analysis techniques
Number of subjects: 18
Study: 9532994

Group type: EXPERIMENTAL
Intervention: Oral metronidazole treatment during pregnancy
Number of subjects: 30363
Study: 8080065

Group type: EXPERIMENTAL
Intervention: Methotrexate 50 mg/m2 on the 3rd, 10th, and 17th postoperative days
Number of subjects: 135

Group type: COMPARATOR
Intervention: Observation (Control)
Number of subjects: 135

Group type: EXPERIMENTAL
Intervention: Methotrexate
Number of subjects: 135
Study: 2642546

Group type: EXPERIMENTAL
Intervention: Combined treatment with CCNU and radiation therapy
Number of subjects: 198

Group type: COMPARATOR
Intervention: Radiation therapy alone
Number of subjects: 198
Study: 998858

Group type: EXPERIMENTAL
Intervention: Elastic compression stockings with gradually decreasing compression from ankle to groin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 0
Study: 31880284

Group type: EXPERIMENTAL
Intervention: T-PRF
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: GTR
Number of subjects: 45

Group type: COMPARATOR
Intervention: OFD alone
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: T-PRF and GTR
Number of subjects: 45
Study: 31046185

Group type: EXPERIMENTAL
Intervention: Physical therapy including desensitization maneuvers of the central nervous system
Number of subjects: 120

Group type: COMPARATOR
Intervention: Surgery
Number of subjects: 120
Study: 28859114

Group type: EXPERIMENTAL
Intervention: Channeled video laryngoscope with pre-loaded endotracheal tube
Number of subjects: 46

Group type: COMPARATOR
Intervention: Curved Macintosh blade video laryngoscope (control)
Number of subjects: 46
Study: 26084809

Group type: EXPERIMENTAL
Intervention: Capecitabine with sorafenib
Number of subjects: 223

Group type: COMPARATOR
Intervention: Capecitabine with placebo
Number of subjects: 223
Study: 23784075

Group type: EXPERIMENTAL
Intervention: Life Skills Training program (21 one-hour sessions in the first year and 12 one-hour sessions in the second year)
Number of subjects: 1048

Group type: EXPERIMENTAL
Intervention: Life Skills Training program
Number of subjects: 1048

Group type: COMPARATOR
Intervention: Control group (no health education or preventive sessions)
Number of subjects: 1048
Study: 21925959

Group type: EXPERIMENTAL
Intervention: Medication review intervention delivered by pharmacists
Number of subjects: 342

Group type: COMPARATOR
Intervention: Control group (no intervention)
Number of subjects: 342
Study: 19587607

Group type: EXPERIMENTAL
Intervention: beta-Blockers
Number of subjects: 738

Group type: EXPERIMENTAL
Intervention: Diuretics
Number of subjects: 738

Group type: COMPARATOR
Intervention: Monotherapy
Number of subjects: 738

Group type: COMPARATOR
Intervention: Awareness
Number of subjects: 738

Group type: COMPARATOR
Intervention: Blood pressure control
Number of subjects: 738
Study: 16625984

Group type: EXPERIMENTAL
Intervention: Dexibuprofen (400 mg t.i.d for 3 days, then 400 mg b.i.d for 11 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Ibuprofen (800 mg t.i.d for 3 days, then 800 mg b.i.d for 11 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Diclofenac (50 mg t.i.d for 3 days, then 50 mg b.i.d for 11 days)
Number of subjects: 60

Group type: COMPARATOR
Intervention: All groups (Dexibuprofen, Ibuprofen, Diclofenac)
Number of subjects: 60
Study: 15630183

Group type: EXPERIMENTAL
Intervention: Rosmarinic acid (RA) 200 mg or 50 mg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Rosmarinic acid (RA)
Number of subjects: 0
Study: 11395032

Group type: EXPERIMENTAL
Intervention: Diabetic patients
Number of subjects: 54

Group type: COMPARATOR
Intervention: Control subjects
Number of subjects: 54
Study: 9205786

Group type: EXPERIMENTAL
Intervention: Cefodizime 2 g once daily (either intravenously or intramuscularly)
Number of subjects: 99
Study: 8197240

Group type: EXPERIMENTAL
Intervention: Electromyographic biofeedback
Number of subjects: 6

Group type: COMPARATOR
Intervention: Conventional physical therapy
Number of subjects: 6